TrialNature cancer2025

Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.

Gabriel Rinnerthaler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.